Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium
Julie M. Vose(University of Nebraska Medical Center), Chengfeng Bi(Sichuan University), Hina Naushad Qureishi(University of Nebraska Medical Center), Sonali M. Smith(University of Chicago), Sunandini Sharma(University of Nebraska Medical Center), Matthew McKinney, Melissa H. Cessna(Intermountain Healthcare), Farshid Kashef(University at Buffalo, State University of New York), Dennis D. Weisenburger(University of Nebraska Medical Center), Amitkumar Mehta(University of Alabama at Birmingham), Deborah M. Stephens(University of North Carolina at Chapel Hill), Adnan Mansoor(University of Minnesota), Caron A. Jacobson(Dana-Farber Cancer Institute), Peter Martin(Northwestern University), Lynette M. Smith(University of Nebraska Medical Center), Timothy C. Greiner(University of Nebraska Medical Center), Barbara Pro(Columbia University Irving Medical Center), Pallawi Torka(Roswell Park Comprehensive Cancer Center), Javeed Iqbal(University of Nebraska Medical Center), Paul M. Barr(University of Rochester Medical Center), Guohua Yu(Qingdao University), Ranjana H. Advani(Stanford Medicine), Jamés O. Armitage(University of Nebraska Medical Center), Michael Crump(University of Toronto), Tycel Phillips(Michigan Medicine), Andrea Anampa‐Guzmán(Mayo Clinic in Arizona), R. Gregory Bociek(University of Nebraska Medical Center), Francisco J. Hernandez‐Ilizaliturri(Roswell Park Comprehensive Cancer Center), Veronika Bachanová(University of Minnesota), Douglas A. Stewart(Alberta Health Services), Brad S. Kahl(UW Health University Hospital), Nadia Khan(Fox Chase Cancer Center), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Brian K. Link(University of Iowa), Matthew A. Lunning(University of Nebraska Medical Center), Shishou Wu(Qingdao University), André Goy(Hackensack University Medical Center), Xing Li(Xinjiang Medical University), Lu Wang(The Central Hospital of Xiao gan), Yuan Ji(Jinan University), Zhaohui Jin(XinHua Hospital), Manali Kamdar(University of Colorado Cancer Center), Hongxia Cheng(Tongji University), Kai Fu(Soochow University)
Cited by 14
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k